Barrier Therapeutics, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Barrier Therapeutics, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Barrier Therapeutics, Inc.. The Group's principal activity is the discovery, development and commercialization of a portfolio of innovative pharmaceutical products to address major medical needs in the field of dermatology. Currently it has multiple product candidates in clinical development, with four of these candidates in or entering Phase III clinical trials. Its advanced product candidates are Sebazole, Zimycan, Hyphanox and Liarozole. Its trademarks are Barrier TherapeuticsTM, SebazoleTM, ZimycanTM, HyphanoxTM, RambazoleTM and HivenylTM. The Group operates in the United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report